Association between metabolic dysfunction-associated steatotic liver disease and cardiovascular disease: New perspectives

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is characterized by systemic insulin resistance and metabolic dysfunction. MASLD/NAFLD elevates the risk of developing cardiovascular disease (CVD). As a quantitative method, bibliometric analysis, illuminates the trajectory of research within a particular field and offers insights into its current state and future directions. In the present study, Citespace (version 6.3.1) was used to comprehensively review the relevant literature for a detailed characterization of the association between MASLD/NAFLD and CVD. This analysis aimed to delineate the historical progression, current research hotspots, and future development trends of MASLD/NAFLD and its relationship with CVD. Our findings highlight a notable surge in research interest in MASLD/NAFLD and CVD over the past 19 years, reflecting an increasing depth of exploration into their interrelationship. In addition to established factors, such as alanine aminotransferase (ALT) and metabolic syndrome, previously overlooked aspects, such as inflammation, gut microbiota, and oxidative stress, have gained significant attention as notable contributors to the pathogenesis of MASLD/NAFLD. By elucidating the intricate association between MASLD/NAFLD and CVD, this study provides prospects for pathophysiological mechanism and preventive strategies for both conditions and provides research insights regarding potential future avenues and focal areas for future investigations.